This was resolved with the discovery of mutations in the immune receptor tyrosine-based activation motive of CD79A or CD79B in 20% of ABC DLBCL, that lead to an effective hijacking of the downstream BCR signaling (13). Here, CD79A is linked to aneurysmal bone cyst.